Richard A Hubner
Overview
Explore the profile of Richard A Hubner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
111
Citations
2535
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wainberg Z, Melisi D, Macarulla T, Pazo Cid R, Chandana S, De La Fouchardiere C, et al.
Future Oncol
. 2025 Feb;
21(7):765-774.
PMID: 39935331
No abstract available.
2.
Alexander S, Aleem U, Jacobs T, Frizziero M, Foy V, Hubner R, et al.
Cancers (Basel)
. 2024 Oct;
16(19).
PMID: 39409965
Biliary tract cancers (BTCs) are aggressive in nature, often presenting asymptomatically until they are diagnosed at an advanced stage. Surgical resection or liver transplantation are potential curative options. However, a...
3.
Netto D, Frizziero M, Foy V, McNamara M, Backen A, Hubner R
Curr Oncol
. 2024 Sep;
31(9):5206-5223.
PMID: 39330013
Pancreatic ductal adenocarcinoma (PDAC) is a significant cause of cancer-associated mortality, with a rising global incidence. A paucity of strong predictive risk factors mean screening programmes are difficult to implement....
4.
Dubash S, Barwick T, Kozlowski K, Rockall A, Khan S, Khan S, et al.
J Nucl Med
. 2024 Feb;
PMID: 38331457
There is a clinical need for F-labeled somatostatin analogs for the imaging of neuroendocrine tumors (NET), given the limitations of using [Ga]Ga-DOTA-peptides, particularly with regard to widespread accessibility. We have...
5.
Lamarca A, Ostios L, McNamara M, Garzon C, Gleeson J, Edeline J, et al.
Cancer Treat Rev
. 2023 Nov;
121:102627.
PMID: 37925878
Precision medicine is a major achievement that has impacted on management of patients diagnosed with advanced cholangiocarcinoma (CCA) over the last decade. Molecular profiling of CCA has identified targetable alterations,...
6.
Passhak M, McNamara M, Hubner R, Ben-Aharon I, Valle J
Best Pract Res Clin Endocrinol Metab
. 2023 Nov;
37(5):101836.
PMID: 37914565
Gastro-enteropancreatic neuroendocrine tumours (GEP-NETs) represent a rare and highly heterogeneous entity with increasing incidence. Based on the results obtained from several trials performed in the last decade, various therapeutic options...
7.
Selection of Chemotherapy in Advanced Poorly Differentiated Extra-Pulmonary Neuroendocrine Carcinoma
Weaver J, Hubner R, Valle J, McNamara M
Cancers (Basel)
. 2023 Oct;
15(20).
PMID: 37894318
Extra-pulmonary poorly differentiated neuroendocrine carcinoma is rare, and evidence for treatment has been limited. In this article, the evidence behind the cytotoxic chemotherapy choices used for metastatic or unresectable EP-PD-NEC...
8.
Clelland S, Nuttall C, Stott H, Cope J, Barratt N, Farrell K, et al.
Healthcare (Basel)
. 2023 Oct;
11(20).
PMID: 37893876
Advanced pancreatic cancer is associated with a poor prognosis, often less than 1 year. Honest prognosis discussions guide early community palliative care services input, facilitating timely advance care planning and...
9.
dAbrigeon C, McNamara M, Le Sourd S, Lamarca A, Lievre A, Bourien H, et al.
Br J Cancer
. 2023 Oct;
129(11):1766-1772.
PMID: 37813958
Background: Cirrhosis is a risk factor for intrahepatic cholangiocarcinoma (iCC). However, its exact prevalence is uncertain and its impact on the management of advanced disease is not established. Methods: Retrospective...
10.
Foy V, McNamara M, Valle J, Lamarca A, Edeline J, Hubner R
Curr Oncol
. 2023 Sep;
30(9):8665-8685.
PMID: 37754543
The treatment of advanced unresectable HCC (aHCC) remains a clinical challenge, with limited therapeutic options and poor prognosis. The results of IMbrave150 and HIMALAYA have changed the treatment paradigm for...